1. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
2. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
3. The Japanese experience with biologic therapies for rheumatoid arthritis
4. 4.Mitoma H, Horiuchi T, Tsukamoto H, et al: Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum2008; 58: 1248-1257.
5. 5.Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I: A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low-dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol2006; 33: 37-44.